Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study by unknown
RESEARCH Open Access
Characteristics and risk factors for 28-day
mortality of hospital acquired fungemias in
ICUs: data from the EUROBACT study
José-Artur Paiva1*, José Manuel Pereira1, Alexis Tabah2,3,4, Adam Mikstacki5, Frederico Bruzzi de Carvalho6,
Despoina Koulenti3,7, Stéphane Ruckly4,8, Nahit Çakar9, Benoit Misset10, George Dimopoulos7, Massimo Antonelli11,
Jordi Rello12, Xiaochun Ma13, Barbara Tamowicz5 and Jean-François Timsit2,4,8,14
Abstract
Background: To characterize and identify prognostic factors for 28-day mortality among patients with hospital-
acquired fungemia (HAF) in the Intensive Care Unit (ICU).
Methods: A sub-analysis of a prospective, multicenter non-representative cohort study conducted in 162 ICUs in 24
countries.
Results: Of the 1156 patients with hospital-acquired bloodstream infections (HA-BSI) included in the EUROBACT
study, 96 patients had a HAF. Median time to its diagnosis was 20 days (IQR 10.5–30.5) and 9 days (IQR 3–15.5) after
hospital and ICU admission, respectively. Median time to positivity of blood culture was longer in fungemia than in
bacteremia (48.7 h vs. 38.1 h; p = 0.0004). Candida albicans was the most frequent fungus isolated (57.1 %), followed
by Candida glabrata (15.3 %) and Candida parapsilosis (10.2 %). No clear source of HAF was detected in 33.3 % of
the episodes and it was catheter-related in 21.9 % of them. Compared to patients with bacteremia, HAF patients
had a higher rate of septic shock (39.6 % vs. 21.6 %; p = 0.0003) and renal dysfunction (25 % vs. 12.4 %; p = 0.0023)
on admission and a higher rate of renal failure (26 % vs. 16.2 %; p = 0.0273) at diagnosis. Adequate treatment started
within 24 h after blood culture collection was less frequent in HAF patients (22.9 % vs. 55.3 %; p < 0.001). The 28-day all
cause fatality was 40.6 %. According to multivariate analysis, only liver failure (OR 14.35; 95 % CI 1.17–175.6; p = 0.037),
need for mechanical ventilation (OR 8.86; 95 % CI 1.2–65.24; p = 0.032) and ICU admission for medical reason (OR 3.87;
95 % CI 1.25–11.99; p = 0.020) were independent predictors of 28-day mortality in HAF patients.
Conclusions: Fungi are an important cause of hospital-acquired BSI in the ICU. Patients with HAF present more
frequently with septic shock and renal dysfunction on ICU admission and have a higher rate of renal failure at
diagnosis. HAF are associated with a significant 28-day mortality rate (40 %), but delayed adequate antifungal therapy
was not an independent risk factor for death. Liver failure, need for mechanical ventilation and ICU admission for
medical reason were the only independent predictors of 28-day mortality.
Background
Bloodstream infection(s) (BSI) in the critically ill patients
are a major cause of morbidity and mortality. The preva-
lence varies between centers, representing 15 % of all
nosocomial infections in a recent, large, multicenter
prevalence study [1]. The prognosis of BSI also varies,
depending on several factors related to the host, the
pathogen and the antimicrobial agent.
Fungi are responsible for around 20 % of all microbio-
logically documented infections in the Intensive Care
Unit (ICU) [1]. The incidence of invasive fungal infec-
tions has increased steadily, namely due to the increas-
ing number of both immunocompromised and critically
ill patients. In the last decades, we faced a worldwide
rise in the prevalence of candidemia, particularly in the
ICU [2–6]. Data from surveillance programs from the
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USA and Europe showed that Candida spp. is respon-
sible for 2–11 % of hospital-acquired BSI (HA-BSI) and
it represents 8.3 % of patients with HA-BSI hospitalized
in ICUs [7]. It is the fourth cause of nosocomial BSI in
the USA and the fifth to the tenth most common patho-
gen in Europe [8–11].
Candidemia is a severe disease linked to significant
morbidity and mortality [3, 12, 13] ranging from 35–75 %
[14, 15]. Outstandingly, after controlling for confounders,
candidemia has been identified as an independent pre-
dictor of mortality [16]. In addition, it prolongs hospital
length of stay and increases costs associated with patient
management [13, 17]. Therefore, it is important to identify
potentially modifiable prognostic factors to improve this
poor outcome. Few independent prognostic factors have
been identified in critically ill patients with candidemia.
Adequate initial therapy is of paramount importance for a
successful outcome. In general, early administration of
antimicrobial agents is associated with a better outcome
[18]. However, contradictory results have been published
on the timing of antifungal therapy [19].
The goal of this sub-analysis of the Epidemiology and
outcome of hospital-acquired bacteremia (EUROBACT)
study was to characterize the population of patients
with hospital-acquired fungemia (HAF) admitted to
ICUs worldwide and to identify prognostic factors for
28-day mortality, including timing of antifungal therapy,
in these patients.
Methods
A prospective observational multicenter international
cohort design was used. The international database was
declared to the CNIL (Commission Nationale de l’Infor-
matique et des Libertés). The French ethics committee
waived the need for informed consent for French cen-
ters. Similar authorization was obtained from countries
such as Portugal (Centro Hospitalar S. João), Poland
(Poznan University of Medical Sciences) and Australia
(Royal Brisbane and Women’s Hospital) and it was
waived in the other countries due to the observational
nature of the study.
Study protocol and definitions
Patients were enrolled if they had a new diagnosis of
HA-BSI and were admitted to an ICU. The study
focused on the first episode of HA-BSI, either being
ICU-acquired or acquired before admission to ICU.
The detailed protocol has been described previously
[7]. Data collected for each patient included the dates
and times of collection and of positivity of the first
positive blood culture; source of infection; presence of
sepsis; severity of illness; comorbidities; and infection
management, including source control, antimicrobial
drugs and adjunctive treatments. Organ dysfunction and
organ failure were defined as Sequential Organ Failure As-
sessment (SOFA) scores >0 and ≥3, respectively. All
study data were obtained from patient files, and no
additional tests were performed for the purpose of the
study. Severity of illness was defined at ICU admission
using the Simplified Acute Physiology Score (SAPS) II
[20] and at HA-BSI diagnosis using the SOFA score
[21]. Comorbidities were assessed using the Charlson
index and the five markers of the Chronic Health
Evaluation from the Acute Physiology and Chronic
Health Evaluation (APACHE) II score, as reported by
Knaus et al. [22]. Clinical variables and relapses or new
episodes of HA-BSI were recorded until ICU discharge,
and the all-cause mortality within 28 days of the first posi-
tive blood culture were ascertained.
Data management and statistical analysis
A control quality check has been detailed previously [7].
The statistical analysis was based only on the first epi-
sode of HA-BSI, as this was the only episode for which
full information was available. The medians and inter-
quartile range (IQR) was computed for continuous data
and Fisher’s exact test or the chi-square test was per-
formed to compare categorical data. We compared char-
acteristics of patients with bacteremia and patients with
fungemia, using univariate hierarchical logistic regres-
sion models, including random effects for country and
center. Time to death was plotted using Kaplan–Meier
curves and compared using a frailty Cox model, treating
the center as a random effect.
For patients with fungemia, risk factors for death were
analyzed using hierarchical models. The variables were
organized into three tiers: country, ICU and patient. To
identify factors associated with day-28 mortality, we built
a three-tiered hierarchical logistic mixed model using
the GLIMMIX procedure in the SAS software. The in-
fluence of country-based and ICU-based variables on the
outcome was included through both fixed and random
effects. Multilevel modeling takes into account the hier-
archical structure of the data, which may manifest as
intra-class correlations. To obtain a conservative esti-
mate of the standard error, a separate random-error
term should be specified for each level of the analysis.
Therefore, to avoid overestimating the significance of
risk factors for death by day 28, we took intra-class cor-
relation into account, and we specified a separate
random-error term for each tier. Variables potentially as-
sociated with day-28 mortality (p values <0.20 by univar-
iate analysis) were introduced into the multivariable
model and selected using a backward approach. Two-
way clinically relevant interactions were tested in the
final model. In all analysis, two-sided p values <0.05
were deemed statistically significant. No correction for
multiple testing was performed.
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Results
A fungus was recovered from the blood in 96 of the
1,156 patients (8.3 %) with HA-BSI admitted to an ICU,
included in the EUROBACT study [7]. Patients with
HAF were mostly male (67.7 %) with a median age of
61 years (IQR 48–73) and a median SAPS II score of 49
(IQR 41–63) (Table 1). They were mostly admitted to
the ICU for medical reasons (63.5 %), 60 % of these with
acute respiratory failure requiring ventilator support and
24 % with a cardiac-related syndrome: 35 % of the patients
had a Charlson co-morbidity index ≥3. A chronic illness
was present in 41.7 % of patients, mainly immuno-
suppressive (15.6 %), cardiovascular (14.6 %) and re-
spiratory (12.5 %) chronic illnesses.
At ICU admission, at least one organ failure was
documented in a significant number of patients (89.6 %).
Respiratory (82.3 %) and cardiovascular (63.5 %) were the
most prevalent organ dysfunctions followed by neuro-
logical (29.2 %) and renal (25 %). Septic shock was diag-
nosed in 39.6 % of the patients and it was present at
diagnosis of HAF in half of the episodes.
The median time to diagnosis of HAF was 20 days (IQR
10.5–30.5) after hospital admission and 9 days (IQR
3–15.5) after ICU admission (Table 2). In fact, more
than half of the episodes (56.3 %) occurred after the
first week in the ICU. However, a significant number
of patients (22.9 %) had already presented with HAF
on ICU admission.
Median time to blood culture positivity in fungemia was
48.7 hours (IQR 33–81). There was no clear source of fun-
gemia in 32 patients (33.3 %) and in 21 patients (21.9 %) it
was catheter-related, based upon culture results yielding
identical microorganisms. The abdomen was the source of
infection in 12 patients (12.5 %) (Table 2). Source control
was required in 43.8 % of patients and was performed in
39.6 % of the patients (Table 2).
The characteristics on admission of patients with fun-
gemia and of those with bacteremia were similar except
for a higher rate of septic shock and renal dysfunction in
fungemic patients (Table 1). At diagnosis, patients with
HAF presented with a significantly higher rate of renal
failure than bacteremic patients. Delay from hospital
admission to HA-BSI diagnosis was not significantly
different between bacteremic and fungemic patients
(13 days (7–25) vs 20 days (10.5–30.5), p = 0.13). Delay of
positivity of culture sampling was significantly longer
for fungemia (38.1 hours (21.1–69.2) vs 48.7 (33–81),
p = 0.0004) (Table 2 and Fig. 1). There was no significant
difference between these two groups of patients in time to
death (Fig. 2).
On comparing baseline characteristics in patients with
ICU-acquired fungemia (n = 74) and HAF (n = 22), the
Table 1 Baseline characteristics of patients with fungemia and patients with bacteremia
Variable Bacteremia patients (n = 1,060) Fungemia patients (n = 96) P value
Age, median (IQR) 62 (49–74) 61 (48–73.5) 0.7077
Male gender, n (%) 691 (65.2) 65 (67.7) 0.6155
Simplified Acute Physiology Score II, median (IQR) 48 (38–59) 49 (41–63) 0.0993
Medical admission, n (%) 611 (57.6) 61 (63.5) 0.1799
Charlson comorbidity index score, n (%) 0.3215
0 361 (34.1) 25 (26)
1–2 367 (34.6) 37 (38.5)
≥3 332 (31.3) 34 (35.4)
At least one chronic illness, n (%) 336 (31.7) 40 (41.7) 0.0629
Immunosuppression, n (%) 136 (12.8) 15 (15.6) 0.5012
Cardiovascular, n (%) 103 (9.7) 14 (14.6) 0.202
Respiratory, n (%) 86 (8.1) 12 (12.5) 0.1286
Renal, n (%) 53 (5) 8 (8.3) 0.1396
Liver, n (%) 40 (3.8) 4 (4.2) 0.9752
At least one organ dysfunction on admission, n (%) 944 (89.1) 86 (89.6) 0.8491
Cardiovascular, n (%) 530 (50) 61 (63.5) 0.0222
Respiratory, n (%) 858 (80.9) 79 (82.3) 0.7319
Neurologic, n (%) 326 (30.8) 28 (29.2) 0.8062
Renal, n (%) 131 (12.4) 24 (25) 0.0023
Septic shock at admission, n (%) 229 (21.6) 38 (39.6) 0.0003
Mortality at 28 days, n (%) 375 (35.4) 39 (40.6) 0.2307
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only difference was more frequent presence of at least
one chronic illness (p <0.01), namely immunosupression
(p <0.01) and cardiovascular disease (p = 0,05) in patients
with HAF (Additional file 1: Table S1). The only signifi-
cant difference in the characteristics of fungemia epi-
sodes at diagnosis, was a higher coagulation SOFA score
in patients with HAF (p <0.01) (Additional file 1: Table
S2).
Candida albicans was the most frequent fungus isolated
(57.1 %) followed by Candida glabrata (15.3 %) and
Candida parapsilosis (10.2 %) (Table 3). Non-albicans
Candida accounted for 39.6 % of HAF in this study.
Table 2 Characteristics of fungemia and bacteremia episodes at diagnosis
Variable Bacteremia patients (n = 1,060) Fungemia patients (n = 96) P value
Delay between ICU admission and BSI, days, median (IQR) 8 (3–16) 9 (3–15.5) 0.9812
Delay between hospital admission and BSI, days, median (IQR) 13 (7–25) 20 (10.5–30.5) 0.1299
Delay to positivity of the blood culture sampling, days, median (IQR) 38.1 (21.1–69.2) 48.7 (33–81) 0.0004
Sepsis syndrome 0.5420
Sepsis, n (%) 136 (12.8) 14 (14.6)
Severe sepsis, n (%) 442 (41.7) 34 (35.4)
Septic shock, n (%) 482 (45.5) 48 (50)
SOFA score 0.4812
0–4, n (%) 256 (24.2) 17 (17.7)
5–7, n (%) 284 (26.8) 24 (25)
8–11, n (%) 300 (28.3) 31 (32.3)
≥12, n (%) 220 (20.8) 24 (25)
SOFA respiratory ≥3, n (%) 499 (47.1) 45 (46.9) 0.9385
SOFA cardiovascular ≥3, n (%) 441 (41.6) 47 (49) 0.2493
SOFA neurological ≥3, n (%) 340 (32.1) 32 (33.3) 0.6578
SOFA renal ≥3, n (%) 172 (16.2) 25 (26) 0.0273
SOFA coagulation ≥3, n (%) 134 (12.6) 15 (15.6) 0.5577
SOFA liver ≥3, n (%) 81 (7.6) 7 (7.3) 0.7845
Need for mechanical ventilation, n (%) 946 (89.2) 84 (87.5) 0.6661
Hypotension, n (%) 529 (49.9) 54 (56.3) 0.3263
Presumed source of infection 0.3336
No clear source, n (%) 242 (22.8) 32 (33.3)
Catheter-related, n (%) 226 (21.3) 21 (21.9)
Respiratory, n (%) 230 (21.7) 14 (14.6)
Intra-abdominal, n (%) 122 (11.5) 12 (12.5)
Urinary, n (%) 43 (4.1) 4 (4.2)
Others, n (%) 67 (6.3) 6 (6.3)
Multiple sources, n (%) 130 (12.3) 7 (7.3)
Source control 0.9820
Not required, n (%) 590 (55.7) 54 (56.3)
Done, n (%) 429 (40.5) 38 (39.6)
Required not done, n (%) 41 (3.9) 4 (4.2)
Delay of adequate treatment <0.0001
<24 h 586 (55.3) 22 (22.9)
>24 h and ≤120 h 335 (31.6) 59 (61.5)
>120 h 40 (3.8) 9 (9.4)
Never 99 (9.3) 6 (6.2)
SOFA Sequential Organ Failure Assessment
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More than one fungus was recovered from the blood
of two of the patients. A mixed (bacterial and fungal)
infection was documented in 15.6 % of the patients
with fungemia.
In this study, 93.8 % of the patients received adequate
treatment: 22.9 % of the patients received adequate
treatment in the first 24 hours after blood culture collec-
tion, which was a significantly lower percentage than for
bacteremia (55.3 %, p <0.001).
The 28-day all-cause mortality was 40.6 % (n = 39),
slightly higher than in bacteremia (35.4 %). Non-
survivors were older (64 years, IQR 50–76 vs 57 years
IQR 46–71, p = 0.318) and had higher SAPS II score (52
IQR 43–63 vs 47 IQR 37–63, p = 0.095) but the differ-
ences were not statistically significant (Table 4). Funge-
mic patients admitted for a medical reason had
significantly higher 28-day mortality (76.9 % vs 54.4 %, p =
0.038). Neither the Charlson comorbidity index nor the
presence of a chronic illness had a significant impact on
the outcome. No association was found between sepsis
syndrome severity at HAF diagnosis and mortality. In uni-
variate analysis, the SOFA score at HA-BSI diagnosis was
associated with a worse outcome. A SOFA score ≥8 was
more frequent in non-survivors (77 % vs 43.8 %, p = 0.004).
Furthermore, non-survivors had significantly higher SOFA
scores for cardiovascular organ (p = 0.015) and respiratory
organ (p = 0.0019) dysfunction. The presumed source of
infection and the pathogen did not affect 28-day mortality.
Delay of adequate treatment also did not affect outcome
(Table 4). The proportion of patients who received ad-
equate antifungal therapy in the first 24 hours after
positive blood culture collection was higher (though not
statistically significant) in non-survivors than that in survi-
vors (28.2 % vs. 19.3 %; p = 0.694).
Fig. 1 Delay to positivity of culture sampling. BC - Blood cultures




















Candidemias patients p = 0.459
Days
No. of patients at risk
Bacteriemias 1060 910 708 538 422 338
Candidemias 96 83 70 58 49 36
Fig. 2 Time to death for fungemic and bacteremic patients
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On multivariable analysis (Table 5), the only variables
independently associated with 28-day mortality were: liver
SOFA score ≥3 (odds ratio (OR) 14.35, 95 % CI 1.17–
175.6, p = 0.037), need for mechanical ventilation (OR
8.86, 95 % CI 1.2–65.24, p = 0.032) and ICU admission for
medical reasons (OR 3.87, 95 % CI 1.25–11.99, p = 0.020).
On multivariate analysis SOFA score was the only risk fac-
tor for death at 28 days in the subpopulation of patients
with ICU-acquired fungemia (p = 0,0085).
Discussion
This prospective, multicenter, observational study dis-
closes that fungemia accounted for 8.3 % of the
hospital-acquired BSI in patients admitted to the ICU.
The mortality rate in HAF was high (40 %), but delayed ad-
equate antifungal therapy was not an independent risk fac-
tor for death. The presence of septic shock and renal
dysfunction on ICU admission and renal failure at BSI
diagnosis were the only factors associated with fungemia in
patients with BSI. In patients with HAF, multivariate logis-
tic regression analysis identified liver SOFA score ≥3, need
for mechanical ventilation and ICU admission for medical
reasons as independent predictors of 28-day mortality.
Candidemia in critically ill patients is considered to be
a severe and life-threatening condition. Recent data
show that ICU and hospital mortality rates are usually
between 36 % and 61 % [5, 6, 14, 15, 18, 23–26]. In our
study, we observed 28 day-mortality of 40.6 % which is
in agreement with former findings [27] and is lower than
the rates observed in recent Australian [19], Brazilian
[26] and Spanish-Italian [18] studies.
Characteristics of bacteremic and fungemic patients at
admission are remarkably similar, namely in terms of the
comorbidity index, immunosuppression and chronic
organ illnesses, and only the presence of septic shock
and renal dysfunction on ICU admission and renal failure
at diagnosis were more frequent in patients with HA-BSI
and fungemia than in those with bacteremia. Although
delay in appropriate treatment was significantly longer for
HAF, the outcome was similar in patients with fungemia
and those with bacteremia.
Kumar et al. [28] observed strong correlation between
shorter time to onset of antimicrobial treatment and re-
duced mortality in patients with septic shock. They showed
that over the first 6 hours after the onset of persistent or
recurrent hypotension, each hour of delay in initiating ef-
fective antimicrobial therapy was associated with a mean
reduction in survival of 7.6 %, including the subgroup
of patients with fungal infection. Nevertheless, the re-
sults of studies addressing the potential benefit of early
antifungal therapy in patients with candidemia are
conflicting.
In a small prospective multicenter study (n = 46 pa-
tients) [14], there was a higher (though not significant,
p = 0.06) probability of survival among patients receiving
early antifungal therapy (within ≤48 hours) compared
with those treated 48 hours or more after the diagnosis
of candidemia. A few years later, an independent associ-
ation between delayed antifungal therapy (>48 hours)
and in-hospital mortality (hazard ratio (HR) 2.1, 95 % CI
1.0–4.4, p = 0.05) was reported by Blot et al. [27]. Ac-
cording to Morrell et al. [29], mortality doubles when
antifungal agents are administered ≥12 hours after the
collection of the first positive blood culture and in an-
other retrospective analysis of 230 patients with candide-
mia [30], initiation of fluconazole ≤24 hours after the
first positive blood culture was associated with a signifi-
cantly lower mortality rate. This positive effect of early
antifungal therapy on survival was further confirmed in
a group of patients with candidemia-associated septic
shock who received treatment within 15 hours of blood
culture collection [31]. Finally, in 216 patients hospitalized
in five teaching hospitals in Italy and Spain (18), who had
septic shock attributable to candidemia, adequate an-
tifungal therapy, meaning both infecting organism
susceptibility and adequate antifungal dosage within
the first 24 hours of culture positivity, was one of the
factors associated with 30-day survival.
However, some recent studies did not observe this
beneficial association between timing of antifungal ther-
apy and mortality in patients with candidemia [32–34].
Kludze-Forson et al. [35] observed a higher in-hospital
mortality rate in patients receiving antifungal therapy
within the first 24 hours (50 %) compared to 24–48
hours (28 %) and more than 48 hours (32 %) after blood
culture collection. More recently, in a large retrospective
study that included 446 patients with candidemia [36],
there was neither a significant association between time
from positive culture to administration of appropriate
antifungal therapy and 30-day mortality, nor between
timing of appropriate antifungal therapy and microbio-
logical resolution of Candida bloodstream infection.









n = 98 (100
%)
n = 75 (76.5
%)
n = 23 (23.5 %)
Candida albicans, n (%) 56 (57,1) 44 (58.7) 12 (52.7)
Candida glabrata, n (%) 15 (15,3) 12 (16.0) 3 (13.0)
Candida parapsilosis, n
(%)
10 (10,2) 7 (9.3) 3 (13.0)
Other Candida, n (%) 7 (7.1) 5 (6.7) 2 (8.7)
Candida tropicalis, n (%) 6 (6.1) 4 (5.3) 2 (8.7)
Other fungi, n (%) 3 (3.1) 2 (2.7) 1 (4.4)
Candida krusei, n (%) 1 (1.0) 1 (1.3) 0
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Table 4 Risk factors for death at 28 days in the subpopulation with candidemia (univariate analysis)
Variable Dead (n = 39 patients) Alive (n = 57 patients) P value
Age, median (IQR) 64 (50–76) 57 (46–71) 0.318
SAPS II, median (IQR) 52 (43–63) 47 (37–63) 0.095
Male, n (%) 28 (71.8) 37 (64.9) 0.448
Medical admission, n (%) 30 (76.9) 31 (54.4) 0.038
Charlson comorbidity index score, n (%) 0.5816
0 8 (20.5) 17 (29.8)
1–2 17 (43.6) 20 (35.1)
≥3 14 (35.9) 20 (35.1)
At least one chronic illness, n (%) 16 (41) 24 (42.1) 0.982
Immunosuppression, n (%) 8 (20.5) 7 (12.3) 0.271
Cardiovascular, n (%) 3 (7.7) 11 (19.3) 0.1245
Respiratory, n (%) 5 (12.8) 7 (12.3) 0.811
Renal, n (%) 2 (5.1) 6 (10.5) 0.431
Liver, n (%) 3 (7.7) 1 (1.8) 0.174
At least one organ dysfunction on admission, n (%) 37 (94.9) 49 (86) 0.187
Cardiovascular, n (%) 25 (64.1) 36 (63.2) 0.901
Respiratory, n (%) 34 (87.2) 45 (78.9) 0.284
Neurologic, n (%) 13 (33.3) 15 (26.3) 0.375
Renal, n (%) 9 (23.1) 15 (26.3) 0.752
Delay between ICU admission and fungemia, days, median (IQR) 8 (4–13) 10 (3–21) 0.229
Delay between hospital admission and fungemia, days, median (IQR) 20 (10–29) 21 (11–32) 0.591
Sepsis syndrome, n (%) 0.301
Sepsis 3 (7.7) 11 (19.3)
Severe sepsis 14 (35.9) 20 (35.1)
Septic shock 22 (56.4) 26 (45.6)
SOFA, n (%) 0.004
0–4 3 (7.7) 14 (24.6)
5–7 6 (15.4) 18 (31.6)
8–11 12 (30.8) 19 (33.3)
≥12 18 (46.2) 6 (10.5)
SOFA score, respiratory, n (%) 0.019
0 4 (10.3) 8 (14)
1 1 (2.6) 7 (12.3)
2 8 (20.5) 23 (40.4)
3 13 (33.3) 16 (28.1)
4 13 (33.3) 3 (5.3)
SOFA score, cardiovascular, n (%) 0.015
0 9 (23.1) 19 (33.3)
1 4 (10.3) 12 (21.1)
2 1 (2.6) 4 (7)
3 4 (10.3) 13 (22.8)
4 21 (53.8) 9 (15.8)
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Table 4 Risk factors for death at 28 days in the subpopulation with candidemia (univariate analysis) (Continued)
SOFA score, neurological, n (%) 0.249
0 13 (33.3) 17 (29.8)
1 5 (12.8) 14 (24.6)
2 7 (17.9) 8 (14)
3 4 (10.3) 11 (19.3)
4 10 (25.6) 7 (12.3)
SOFA score, renal, n (%) 0.122
0 11 (28.2) 32 (56.1)
1 8 (20.5) 10 (17.5)
2 5 (12.8) 5 (8.8)
3 5 (12.8) 3 (5.3)
4 10 (25.6) 7 (12.3)
SOFA score, coagulation, n (%) 0.125
0 19 (48.7) 42 (73.7)
1 6 (15.4) 3 (5.3)
2 4 (10.3) 7 (12.3)
3 6 (15.4) 4 (7)
4 4 (10.3) 1 (1.8)
SOFA score, liver, n (%) 0.142
0 26 (66.7) 46 (80.7)
1 6 (15.4) 6 (10.5)
2 1 (2.6) 4 (7)
3 6 (15.4) 1 (1.8)
Need for mechanical ventilation, n (%) 37 (94.9) 47 (82.5) 0.094
Hypotension, n (%) 25 (64.1) 29 (50.9) 0.208
Presumed source of infection, n (%) 0.573
No clear source 12 (30.8) 20 (35.1)
Catheter-related 6 (15.4) 15 (26.3)
Intra-abdominal 8 (20.5) 4 (7)
Respiratory 6 (15.4) 8 (14)
Urinary 2 (5.1) 2 (3.5)
Others 2 (5.1) 4 (7)
Multiple sources, n (%) 3 (7.7) 4 (7)
Delay of adequate treatment, n (%) 0.694
<24 h 11 (28.2) 11 (19.3)
>24 h and ≤48 h 9 (23.1) 14 (24.6)
>48 h and ≤120 h 12 (30.8) 24 (42.1)
>120 h or never 7 (17.9) 8 (14)
Antifungal treatment on the day of blood culture sampling, n (%) 8 (20.5) 8 (14) 0.491
Candida pathogen, n (%) 0.693
Candida albicans 23 (59) 33 (57.9)
Candida parapsilosis 5 (12.8) 5 (8.8)
Other fungus 11 (28.2) 19 (33.3)
SOFA Sequential Organ Failure Assessment
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Studies addressing only ICU-acquired candidemia, also
failed to show this positive impact [19, 25, 37]. In the
study of Marriott et al. [19], mean time to initiation
of antifungal therapy was similar for non-survivors and
survivors (2.0 ± 1.3 days vs 2.3 ± 1.6 days, p = 0.13), and
Charles et al. [37] also observed that early therapy
(≤48 hours after onset of candidemia) did not improve the
outcome of patients with candidemia. Finally, a prospect-
ive, Spanish multicenter study showed that inadequate an-
tifungal therapy was a factor independently associated
with early mortality (0–7 days) in candidemia, but it had
no impact on late mortality (8–30 days) [38].
In our study, four factors may contribute to the ab-
sence of impact of delayed adequate antifungal therapy
on mortality. First, in critically ill patients, antifungal
therapy is more likely to be started earlier than in non-
ICU patients and, in fact, 22.9 % of the patients received
adequate treatment within the first 24 hours and almost
half of them within the first 48 hours after blood culture
collection. Second, among critically ill patients any rela-
tionship between mortality and initiation of antifungal
therapy may be hidden by the power of the patient’s
acute illness as a determinant of outcome. Third, only
half of our fungemia patients had septic shock at BSI
diagnosis and the impact of early therapy is understand-
ably higher in this subgroup of patients. Finally, timing
to source control is a possible confounder that could not
be analyzed, namely we did not collect data on the pres-
ence of a catheter, except on removal if it was deemed
the source of the bloodstream infection.
Few prognostic factors have been identified in ICU
patients with candidemia. In this cohort, the only independ-
ent prognostic factors associated with 28-day mortality
were liver SOFA score ≥3, need for mechanical ventilation
and ICU admission for medical reasons. Acute severity of
illness is one important prognostic factor in candidemia.
Among candidemic patients, the severity of organ dysfunc-
tion at fungemia onset evaluated by the SOFA score is a
risk factor for mortality [39]. In our study, only liver failure
was independently associated with 28-day mortality. In
Candida bloodstream infection, this association between
liver disease and outcome was previously reported but only
for patients with chronic liver illness, which has a signifi-
cant HR as an independent risk factor for 30-day mortality
(HR 2.15, 95 % CI 1.48–3.13, p <0.001) [34]. There is
also a relationship between other scores, such as the
APACHE II score, and mortality in candidemic patients
[14, 23–25, 40]. In our study, we used the SAPS II
score but despite being higher in non-survivors (52 vs 47,
p = 0.095), we could not prove it was an independent risk
factor for mortality. A possible explanation is the fact that
this score was calculated on admission and may not reflect
the severity of the patients at the time of BSI diagnosis.
The need for mechanical ventilation as an independent
risk factor for mortality has also been reported by sev-
eral authors. In a prospective, multicenter, observational
French study [5], the use of mechanical ventilation in-
creased the odds of dying in the ICU 2.54 times (95 %
CI 1.33–4.82, p = 0.0045). A similar result was reported
in another large retrospective study (n = 987 patients
with candidemia) [41] that showed an independent associ-
ation between mechanical ventilation and 30-day mortal-
ity (OR 2.61, 95 % CI 1.81–3.78, p <0.001). An even
higher impact was observed in a study with 173 ICU-
acquired episodes of candidemia, in which the need of
mechanical ventilation was associated with a four times
increased risk of death (95 % CI 1.93–8.41, p <0.001) [19].
Almirante et al. also reported that intubation (OR 7.5,
95 % CI 2.6–21.1) was associated with higher odds of 30-
day mortality in a cohort of 345 patients with candidemia,
of whom 33 % were in the ICU at diagnosis [42].
In our cohort, medical patients had a lower probability
of survival. Interestingly, the same result was reported by
Charles et al. [37] a few years ago in a small study of 51
ICU patients with candidemia, in which medical patients
had a higher mortality rate compared to surgical patients
(85 % vs 45.2 %) and prior surgery was an independent fac-
tor associated with survival (HR 0.25, 95 % CI 0.09–0.67,
p <0.05). Other authors [19] observed that the chances of
dying with candidemia are 6.97 times higher in patients
without multi-trauma (95 % CI 1.64–29.67, p = 0.009).
Although our study is multicenter, prospective and
includes a significant number of patients, it has some
limitations. It is not representative of the populations
of healthcare systems in the 24 participating countries, and
in some countries the number of patients included was
very small. Each participating ICU performed investiga-
tions and laboratory testing according to their local proto-
cols. The data were entered into the electronic case report







Delay of adequate treatment
≤24 h, n (%) Reference 1 0.8069
>24 h and ≤48 h, n (%) −0.24 (0.74) 0.79 (0.18; 3.41) 0.7466
>48 h and ≤120 h, n (%) −0.61 (0.66) 0.54 (0.15; 2.0)] 0.3570
>120 h or never, n (%) −0.15 (0.90) 0.86 (0.15; 5.14) 0.8717
Medical admission 1.35 (0.57) 3.87 (1.25; 11.99) 0.0197
SOFA score, liver (≥3) 2.66 (1.26) 14.35 (1.17; 175.6) 0.0373
Need for mechanical
ventilation
2.18 (1.00) 8.86 (1.2; 65.24) 0.0325
Variables entered into the selection were the Simplified Acute Physiology
Score II at ICU admission (per point); medical admission; septic shock at
admission; type of ICU (open/closed); Sequential Organ Failure Assessment
(SOFA) score, coagulation (≥3); SOFA score, liver (≥3); SOFA score, neurological
(≥3); SOFA score, renal (≥3); mechanical ventilation and delay of
adequate treatment
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form by investigators at each center, which may have in-
creased the risk of inconsistency. Finally, some important
variables with potential impact on the outcome were not
considered, namely the antifungal agent used, its appropri-
ateness and the timing of central venous catheter removal.
Conclusion
In summary, this multicenter international study showed
that fungi are an important cause of HA-BSI in patients
admitted to the ICU. No significant differences were ob-
served between patients with bacteremia and fungemia,
except for the presence of septic shock and renal dys-
function on ICU admission and renal failure at diagno-
sis, which were more frequent in HAF. Fungemia is
significantly associated with 28-day all-cause mortality.
We were not able to detect an independent association
between timing of antifungal therapy and outcome, and
only liver failure, need for mechanical ventilation and
ICU admission for medical reasons were independent
risk factors associated with mortality.
Key messages
 A fungus is likely to be the cause of a hospital-
acquired BSI in patients with septic shock and renal
dysfunction on ICU admission or with renal failure
at BSI diagnosis
 In patients with hospital-acquired fungemia, the
presence of liver failure, the need for mechanical
ventilation and ICU admission for medical reasons
significantly increase the odds of dying at day 28
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